Agnieszka O. S.
- Country
- Poland
- Department
- Dermatology
Research Overview
- Efficacy and Safety Evaluation of Vilobelimab in Ulcerative Pyoderma Gangrenosum: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial
- A double-blind, randomized, placebo-controlled trial to evaluate the efficacy, pharmacokinetics and safety of remibrutinib (LOU064) for 24 weeks in adolescents from 12 to less than 18 years of age with chronic spontaneous urticaria inadequately controlled by H1-antihistamines followed by an optional open-label extension for up to another 3 years and an optional safety long-term treatment-free follow-up period for up to an additional 3 years.
- Evaluation of Amlitelimab Monotherapy in Maintaining Treatment Response in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis
Data & Insights
Has run more than one trial at 120 of 284 partner sites.
Specializations
Inflammatory Dermatoses
Clinical research activity centers on chronic inflammatory skin disease, with a strong focus on atopic dermatitis, moderate-to-severe plaque psoriasis, and prurigo nodularis. The portfolio also includes hidradenitis suppurativa, reflecting sustained interest in complex, relapsing dermatologic conditions that require targeted immunomodulatory treatment.
- Atopic dermatitis
- Plaque psoriasis
- Prurigo nodularis
- Hidradenitis suppurativa
Work in this area is closely aligned with therapies aimed at controlling persistent skin inflammation, itch, and lesion burden in patients with difficult-to-manage disease.
Urticaria and Mast Cell-Related Disorders
Another major therapeutic domain involves chronic spontaneous urticaria and chronic inducible urticaria, including symptomatic dermographism, cold urticaria, and cholinergic urticaria. This area highlights interest in conditions marked by recurrent wheals, pruritus, and impaired quality of life.
- Chronic spontaneous urticaria
- Chronic inducible urticaria
- Symptomatic dermographism
- Cold urticaria
The clinical focus extends to novel biologic and immune-directed approaches for patients who remain symptomatic despite standard antihistamine-based care.
Autoimmune and Neutrophilic Skin Disease
Research involvement also includes cutaneous lupus erythematosus and pyoderma gangrenosum, with attention to severe inflammatory skin disorders that combine autoimmune and neutrophilic features. The portfolio includes ulcerative disease manifestations associated with substantial skin damage and treatment resistance.
- Cutaneous lupus erythematosus
- Pyoderma gangrenosum
- Ulcerative pyoderma gangrenosum
This area is linked to therapies targeting immune dysregulation and skin ulceration in refractory dermatologic disease.
Hair Loss and Immune-Mediated Alopecia
The investigator is engaged in clinical work on alopecia areata, a major immune-mediated hair disorder with significant therapeutic need. The research emphasis is on restoring hair growth in patients with severe to very severe disease.
- Alopecia areata
This field reflects interest in immune pathway modulation for hair follicle-related disease.
Heart Failure and Cardiovascular Comorbidity
Beyond dermatology, the trial portfolio includes heart failure with reduced ejection fraction, acute heart failure, and related pulmonary hypertension associated with cardiac disease. This creates a distinct cardiovascular interest alongside the dermatologic program.
- Heart failure with reduced ejection fraction
- Acute heart failure
- Pulmonary hypertension
The therapeutic focus in this area includes improving cardiac status and disease-related health outcomes in patients with advanced heart failure.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.